H.R. 3810 · 118th Congress
Drug Origin Transparency Act of 2023
Key: what the circles and colors mean
Each circle is a bill. The ring fills as it moves through Congress:
Under the number: the Yea · Nay count of its final (or latest) recorded vote. On a member's page, the small badge is how that member voted: Y Yea / Aye, N Nay / No, P Present, – Not voting.
Gold and violet are only for Yea and Nay; they never mean a party. A member's party is the letter on their photo.
Never voted on. It didn't reach a floor vote before the 118th Congress ended, so it expired. A bill has to be introduced again to be considered in a new Congress.
D
EshooSponsor4 cosponsors · 4 D
0 signed on when it was introduced; the rest joined later. Cosponsors who withdrew aren't shown.
This bill requires drug manufacturers to report on the suppliers of ingredients used in their products.
What it does: CRS summary · Introduced in House · Jun 5, 2023
Drug Origin Transparency Act of 2023
This bill requires drug manufacturers to report on the suppliers of ingredients used in their products.
Specifically, drug manufacturers must report information relating to the supply chain of their products, including the suppliers of active ingredients and the amount of drugs that are manufactured using those ingredients. Drug manufacturers must also include information about the manufacturers of ingredients on the labels of their products.
Written by the nonpartisan Congressional Research Service. All summary versions on Congress.gov
About this bill and sources
Official title: Drug Origin Transparency Act of 2023
Latest action (Jun 9, 2023): Referred to the Subcommittee on Health.
Policy area: Health · Origin: House · Introduced: Jun 5, 2023
Official page on Congress.gov · Bill text (GovInfo) · Status record (XML)
No recorded floor vote found.